GlaxoSmithKline Plc will focus on building its pharmaceutical pipeline this year while executing a merger of its consumer healthcare business with that of Pfizer Inc. This was the message delivered by Emma Walmsley, the chief executive, following the release of first-quarter results on 1 May which showed a 6% rise in turnover to £7.7 billion and an operating profit of £1.43 billion, up by 15% from a year earlier. The operating margin was 18.6%.
